Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ViaCyte logo — Regenerating Health: Transforming the lives of patients with...

ViaCyte

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes

Founded 1999 United States San Diego, United States 35 employees Series D Total: $235.55M Biotechnology, Health Care +1

General Information

Company Name ViaCyte
Founded Year 1999
Location United States San Diego, United States
Founders / Decision Makers
Team member Team member Team member
Employees 35
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with ViaCyte. To contact ViaCyte, visit viacyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ViaCyte compare?

A PDF of ViaCyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ViaCyte soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ViaCyte

ViaCyte is a biotechnology startup from the United States, focused on developing revolutionary cell replacement therapies for long-term diabetes treatment, aiming to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are rooted in the directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, implanted in durable and retrievable cell delivery devices. The company has garnered attention through its collaborative partnerships with esteemed companies such as CRISPR Therapeutics and W.L. Gore & Associates, aiming to accelerate and expand its efforts. ViaCyte's pipeline includes the PEC-Direct product candidate, which is currently undergoing clinical evaluation and delivers PEC-01 cells in a non-immunoprotective device, catering to type 1 diabetes patients with specific conditions. Additionally, the PEC-Encap product candidate delivers pancreatic islet progenitor cells in an immunoprotective device, intended for all type 1 diabetes patients. Recently, ViaCyte attracted a Series D investment on 22 April 2021, with notable backers including Invus, Adage Capital Management, Asymmetry Ventures, and Artis Ventures (AV). The company showcases promising potential with its emphasis on regenerative medicine, aiming to transform the lives of patients with insulin-requiring diabetes, making it a compelling prospect for venture capital investment.

Business keywords: Regenerative Medicine, Cell Therapy, Diabetes Treatment, Stem Cell Therapy, Pancreatic Islet Progenitor Cells, Type 1 Diabetes, Insulin Replacement Therapy, Clinical Evaluation, Immuno-evasive Therapy, Collaborative Partnerships, CRISPR Therapeutics, W.L. Gore & Associates, Chronic Disease Management, Medical Device Innovation, Cell Differentiation

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Series D Undisclosed 4
Invus Adage Capital Management Asymmetry Ventures
Invus, Adage Capital Management +2
22 Apr 2021
Series D $32.65M 4
RA Capital Management Sanderling Ventures
RA Capital Management, Sanderling Ventures +2
20 Mar 2020
Series D $80.00M 4
RA Capital Management Sanderling Ventures
RA Capital Management, Sanderling Ventures +2
29 Nov 2018
Convertible Note $10.00M 1
W.L. Gore & Associates
25 Sep 2018
Grant Undisclosed 1
National Institute of Diabetes and Digestive and Kidney Diseases
17 Apr 2018
Grant $1.40M 1
California Institute for Regenerative Medicine
15 Dec 2017
Venture Round $10.00M 3
W.L. Gore & Associates, JDRF (The Juvenile Diabetes Research Foundation) +1
22 May 2017
Grant $3.90M -
21 Jul 2016
Grant $16.60M 1
California Institute for Regenerative Medicine
11 Sep 2014
Venture Round $20.00M 2
Johnson & Johnson Robotics and Digital Solutions, Janssen
25 Aug 2014

View All 15 Funding Rounds

ViaCyte Alternatives & Competitors

View All Alternatives
ViaCyte vs
Kadimastem Ltd.
Kadimastem Ltd. Israel

A clinical stage biotech company using PLATFORM TECH for the Manufacturing of cells for ALS and Diab...

Grant
32 employees
Biotechnology, Health and Wellness
Compare ViaCyte vs Kadimastem Ltd.
ViaCyte vs
BlueRock Therapeutics
BlueRock Therapeutics United States

Striving to transform the treatment of disease by harnessing the power of cell therapy

Acquired
478 employees
Biopharma, Biotechnology
Compare ViaCyte vs BlueRock Therapeutics
ViaCyte vs
Stemedica Cell Technologies, Inc
Stemedica Cell Technologies, Inc United States

Developing Breakthrough Progenitor Cell and Protein Therapeutics

Series B
16 employees
Biotechnology, Health Care
Also compare with: ViaCyte vs TreeFrog Therapeutics TreeFrog Therapeutics View all alternatives

FAQ About ViaCyte

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes
ViaCyte was founded in 1999.
ViaCyte is headquartered in San Diego, United States.
ViaCyte operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Regenerative Medicine, Cell Therapy, Diabetes Treatment and Stem Cell Therapy.
ViaCyte has approximately 35 employees.
ViaCyte has completed 15 funding rounds, raising a total of $235.55M. The latest funding stage is Series D.
Top alternatives and competitors to ViaCyte include Kadimastem Ltd., BlueRock Therapeutics, Stemedica Cell Technologies, Inc, Blue Cell Therapeutics, PrimeCell Bioscience, a.s.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ViaCyte and Kadimastem Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ViaCyte, https://bouncewatch.com/company/viacyte, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout